Adult Psychiatry· 12 min read
Chemical Imbalance and Depression: What the Science Actually Shows
Published: May 2026 | By: Dr. Baghel | Category: Adult Psychiatry
The chemical imbalance depression theory is one of the most widely repeated explanations in medicine. Patients hear it from doctors. Pharmaceutical advertisements promoted it for decades. The premise is simple: depression results from low serotonin levels in the brain, and antidepressants correct that deficit. The explanation is intuitive, memorable, and almost entirely unsupported by the scientific evidence.
For the full range of evidence-based options once the old story is set aside, see my guide to depression treatment in North Carolina.
If the chemical-imbalance story is fading, something has to replace it. I lay out the metabolic alternative in metabolic psychiatry: what the evidence actually shows.
This does not mean antidepressants are ineffective. It does not mean depression is not a real medical condition. It means the story patients have been told about how their medication works is oversimplified to the point of inaccuracy. Understanding what the research actually shows matters for treatment decisions, for setting realistic expectations, and for identifying what else might be contributing to depressive symptoms beyond serotonin.
This shift reached federal policy in 2026, when HHS leaned on prevention and transparency in its MAHA psychiatric overprescribing plan.
For patients in North Carolina seeking psychiatric care that addresses the full clinical picture, including hormones, sleep, and lifestyle factors alongside medication when indicated, visit the psychiatry services page for evaluation options.
For help applying this to your own care, see working with an online psychiatrist for depression in North Carolina.
Focus problems can trace to the same upstream causes as mood problems. An adult ADHD evaluation checks those metabolic contributors, like thyroid and iron, before the problem gets pinned on brain chemistry alone.
What the Chemical Imbalance Theory Actually Claims
The serotonin hypothesis emerged in the 1960s from observations that certain drugs affected mood. Reserpine, a blood pressure medication, depleted monoamines (including serotonin) and sometimes caused depression. Iproniazid, a tuberculosis drug, inhibited monoamine oxidase and improved mood. Researchers proposed that depression might result from deficient monoamine neurotransmission, particularly serotonin.
The hypothesis gained traction when selective serotonin reuptake inhibitors (SSRIs) entered the market in the late 1980s. Marketing materials simplified the science into a consumer-friendly message: depression is caused by low serotonin, and SSRIs correct the imbalance by keeping more serotonin available in the brain. This framing appeared in direct-to-consumer advertising, patient education materials, and clinical conversations for three decades.
The problem is that this explanation was never well supported by evidence, and the scientific community has known this for years. The gap between what researchers understood and what patients were told widened over time.
What the 2022 Umbrella Review Found
In July 2022, a research team led by Joanna Moncrieff at University College London published a systematic umbrella review in Molecular Psychiatry examining decades of serotonin research. The review synthesized evidence from six major research areas: serotonin and metabolite levels in body fluids, serotonin receptor binding, serotonin transporter levels, tryptophan depletion studies, serotonin transporter gene associations, and gene-environment interactions (PMID: 35854107).
The findings were consistent across domains. Studies comparing serotonin levels in depressed patients versus healthy controls found no reliable differences. Research on serotonin receptors and transporters produced weak, inconsistent results that were often confounded by prior antidepressant use. Tryptophan depletion (artificially lowering serotonin precursors) did not reliably induce depression in healthy volunteers. Large genetic studies found no association between serotonin transporter gene variants and depression risk.
The authors concluded that the evidence does not support the hypothesis that depression is caused by lowered serotonin activity or concentrations. Some findings even suggested that long-term antidepressant use might reduce serotonin concentrations, the opposite of what the chemical imbalance theory would predict.
The Scientific Debate
The Moncrieff review generated substantial academic response. A group of 36 researchers published a critique in the same journal, arguing that the review contained methodological weaknesses, selective reporting, and oversimplification of neuropsychopharmacological findings (PMID: 37322065). They noted that the serotonin system is implicated in depression through mechanisms more complex than simple “low serotonin” and that tryptophan depletion studies show mood effects in patients with a history of depression, even if not in healthy volunteers.
The debate matters less for the average patient than the underlying agreement: the simple “low serotonin causes depression” story is not accurate. Even critics of the Moncrieff review do not defend the chemical imbalance explanation as it was communicated to patients. They argue instead that serotonin plays a more nuanced role in neural circuitry and plasticity.
If Not Serotonin Levels, Then How Do Antidepressants Work
The evidence that antidepressants have clinical effects is separate from the question of mechanism. A 2018 network meta-analysis in The Lancet examined 522 trials involving nearly 117,000 patients and found that all 21 antidepressants studied were more effective than placebo for acute treatment of major depressive disorder (PMID: 29477251). The medications work. The question is how.
Current research points toward neuroplasticity rather than neurotransmitter levels. Antidepressants appear to promote the growth and connection of neurons, particularly in brain regions affected by chronic stress. This process involves brain-derived neurotrophic factor (BDNF), a protein that supports neuronal survival, growth, and synaptic plasticity.
A 2021 study published in Cell demonstrated that antidepressants, including fluoxetine (Prozac), imipramine, and ketamine, bind directly to TrkB receptors, which are activated by BDNF (PMID: 33606976). This binding facilitates neuroplasticity regardless of effects on serotonin, norepinephrine, or glutamate. The finding suggests that the neuroplasticity pathway may be a common mechanism across antidepressant classes, explaining why drugs with different neurotransmitter profiles can all improve depression.
This neuroplasticity model also explains the delayed onset of antidepressant effects. SSRIs increase synaptic serotonin within hours, but clinical improvement typically takes two to four weeks. The delay corresponds to the time required for neuroplastic changes, including new dendritic connections and neurogenesis in the hippocampus, to occur.
The same neuroplasticity pathway appears to underlie the therapeutic effects of psychedelic compounds that work through similar mechanisms, which is one reason psilocybin, ketamine, and related investigational therapies are receiving renewed clinical attention for treatment-resistant mood disorders.
That same neuroplasticity logic is driving federal policy, which I cover in the executive order on psychedelic therapy.
Psilocybin is the clearest test of that idea. For how it engages the same neuroplasticity machinery at the 5-HT2A receptor, see how psilocybin drives that plasticity.
Psilocybin has a long history behind that research. For how it went from teonanácatl to Hofmann’s 1958 synthesis to Schedule I, see the history of psilocybin.
Why This Matters for Your Treatment
Understanding that depression is not simply “low serotonin” has practical implications for care. If the chemical imbalance model were accurate, treatment would be straightforward: measure serotonin, prescribe medication to raise it, confirm improvement. Reality is more complex, which explains why antidepressant response varies so widely between individuals and why medication alone often produces incomplete remission.
Medication Still Has a Role
Rejecting the chemical imbalance explanation does not mean rejecting medication. Antidepressants remain a legitimate, evidence-based treatment option for major depressive disorder. The Cipriani meta-analysis demonstrated efficacy across multiple drug classes. For moderate to severe depression, medication combined with psychotherapy typically produces better outcomes than either alone.
What changes is the framing. Antidepressants are not “correcting a deficiency” in the way insulin corrects diabetes. They are pharmacological tools that promote neuroplastic changes, creating conditions under which recovery can occur. This framing sets more accurate expectations and reduces the stigma some patients feel about “needing a chemical to be normal.”
Other Factors Deserve Evaluation
If depression is not simply a serotonin problem, then treatment should not be limited to serotonin-targeting medications. Multiple biological systems influence mood, and dysfunction in any of them can produce or exacerbate depressive symptoms.
Hormones
Testosterone deficiency produces symptoms that overlap substantially with depression: fatigue, low motivation, irritability, decreased concentration, reduced interest in activities. A 2019 meta-analysis in JAMA Psychiatry found that testosterone treatment was associated with significant reduction in depressive symptoms, particularly in men with confirmed hypogonadism (PMID: 30427999). Men with treatment-resistant depression or symptoms that include low libido, reduced morning erections, and unexplained fatigue should have testosterone levels evaluated.
Inflammation
Elevated inflammatory markers correlate with depression severity and predict poor response to standard antidepressants. The gut-brain axis, which connects intestinal health to brain function, is increasingly recognized as relevant to mood disorders. Patients with chronic GI symptoms alongside depression may benefit from interventions targeting inflammation. Some peptides with anti-inflammatory properties are being studied for mood applications.
Sleep
Sleep disruption both causes and results from depression. Circadian rhythm dysfunction affects neurotransmitter synthesis, cortisol regulation, and inflammatory pathways. Addressing sleep architecture is often necessary for full recovery, not merely a side benefit.
Metabolic Health
Obesity, insulin resistance, and metabolic syndrome are associated with higher depression rates and poorer treatment outcomes. GLP-1 medications used for weight loss have shown mood benefits in some studies, potentially through anti-inflammatory effects and improved metabolic signaling.
For patients who want that side managed clinically, the practice runs medical weight loss in North Carolina as a physician-led plan, with the metabolic labs and mood followed together.
The Answer Patients Need
Patients who learn that the chemical imbalance story is oversimplified often ask the obvious follow-up: “Then why should I take my antidepressant?” The answer requires honesty about uncertainty.
Antidepressants help many people with depression. The mechanism is not fully understood, but the evidence for clinical benefit is solid. Current research suggests they work by promoting neuroplasticity, helping the brain form new connections and recover from stress-induced changes. This is not the simple “fixing a deficit” model, but it is a legitimate biological effect.
Whether medication is the right approach for a given patient depends on symptom severity, treatment history, contributing factors, and individual values. For some patients, medication is essential. For others, addressing underlying issues (hormonal, inflammatory, sleep-related, or psychosocial) may reduce or eliminate the need for pharmacotherapy. For many, the answer is both.
The goal is not to reject psychiatric medication but to move beyond an oversimplified model that has outlived its usefulness. Depression is a complex condition with multiple contributing pathways. Treatment should reflect that complexity.
How I Approach Depression Treatment
In my practice, I do not assume that every depressed patient needs an SSRI, nor do I assume that medication is unnecessary. The evaluation process is designed to identify what is actually driving the symptoms.
For men, that evaluation includes hormone assessment. Testosterone levels are not routinely checked in psychiatric settings, despite substantial symptom overlap between hypogonadism and depression. Patients who have tried antidepressants without full response, or whose symptoms include prominent fatigue, low motivation, and sexual dysfunction, may have an unaddressed hormonal component. The TRT program addresses this population.
For patients with gut symptoms, chronic inflammation, or interest in regenerative approaches, peptide therapy may be relevant. Certain peptides have demonstrated effects on neuroplasticity, inflammation, and gut-brain signaling in preclinical research.
For patients who benefit from traditional psychiatric medication, the goal is accurate diagnosis, appropriate medication selection, and ongoing monitoring. The fact that the chemical imbalance model is oversimplified does not change the clinical utility of pharmacotherapy when it is indicated. For patients who have tried multiple antidepressants without improvement, a thorough evaluation for treatment-resistant depression can identify factors that were missed.
Frequently Asked Questions
Is depression caused by a chemical imbalance?
The evidence does not support the simple “chemical imbalance” explanation that was widely promoted for decades. A 2022 umbrella review in Molecular Psychiatry found no consistent evidence that depression is caused by low serotonin levels or reduced serotonin activity. Depression is a complex condition influenced by genetics, stress, hormones, inflammation, sleep, and other factors. Antidepressants appear to work through neuroplasticity mechanisms rather than by “correcting” a neurotransmitter deficit.
Do antidepressants work if there is no chemical imbalance?
Yes. The clinical efficacy of antidepressants is well established by large meta-analyses. A 2018 Lancet study of 522 trials found all 21 antidepressants studied were more effective than placebo. The mechanism is not fully understood, but current research suggests antidepressants promote neuroplasticity by enhancing BDNF signaling and TrkB receptor activity. They help the brain form new neural connections and recover from stress-induced changes, which is different from “correcting a chemical deficit” but still a legitimate biological effect.
Should I stop taking my antidepressant?
No. Learning that the chemical imbalance explanation is oversimplified is not a reason to discontinue medication. If your antidepressant is helping, the clinical benefit is real regardless of the mechanism. Stopping psychiatric medication abruptly can cause withdrawal symptoms and relapse. Any changes to medication should be discussed with your prescribing clinician and tapered appropriately if discontinuation is appropriate for your situation.
What else should be evaluated if I have depression?
Depression has multiple potential contributing factors beyond neurotransmitter function. Hormone levels (particularly testosterone in men and thyroid function in both sexes), inflammatory markers, sleep quality, metabolic health, and psychosocial stressors all influence mood. Patients with incomplete response to standard antidepressants, or whose symptoms include prominent fatigue, low motivation, and sexual dysfunction, may benefit from broader evaluation.
Can low testosterone cause depression symptoms?
Yes. Testosterone deficiency produces symptoms that overlap substantially with depression: fatigue, low motivation, irritability, poor concentration, and decreased interest in activities. Meta-analyses have found that testosterone treatment reduces depressive symptoms in men with confirmed hypogonadism. Testosterone levels are not routinely checked in psychiatric settings, which means this contributing factor is often missed.
Depression Treatment That Looks at the Full Picture
Schedule a consultation to discuss your symptoms, treatment history, and whether hormonal, metabolic, or other factors may be contributing.
Baghel Psychiatry, PLLC | Shantanu Baghel, DO | (910) 612-6015 | sbaghel@thebh.us
References
1. Moncrieff J, Cooper RE, Stockmann T, et al. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry. 2023;28(8):3243-3256. PMID: 35854107.
2. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366. PMID: 29477251.
3. Casarotto PC, Girych M, Fred SM, et al. Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell. 2021;184(5):1299-1313. PMID: 33606976.
4. Walther A, Breidenstein J, Miller R. Association of testosterone treatment with alleviation of depressive symptoms in men: a systematic review and meta-analysis. JAMA Psychiatry. 2019;76(1):31-40. PMID: 30427999.
5. Jauhar S, Arnone D, Baldwin DS, et al. A leaky umbrella has little value: evidence clearly indicates the serotonin system is implicated in depression. Mol Psychiatry. 2023;28(8):3149-3152. PMID: 37322065.
6. Yang T, Nie Z, Shu H, et al. The role of BDNF on neural plasticity in depression. Front Cell Neurosci. 2020;14:82. PMID: 32351365.
Monthly plans cover Dr. Baghel’s clinical services only (evaluation, monitoring, medication management, ongoing care). Labs and medications are paid separately by the patient. This article is for educational purposes only and is not medical advice. Do not start, stop, or modify any medication without consulting your prescribing clinician.